It takes GUTS to be BOLD: A look at the new biotech tick­ers

As the pub­lic mar­kets heat up in biotech, in­dus­try in­sid­ers ex­pect a small drum­beat of IPOs lat­er this spring, and that means a new set of stock tick­ers to track.

Next up is BOLD, the pro­posed name of Bound­less Bio’s Nas­daq stock. Us­ing that name would mark a re­turn for the tick­er, which freed up af­ter Astel­las bought Au­dentes Ther­a­peu­tics for $3 bil­lion in 2019. Bound­less is ex­pect­ed to make its Wall Street de­but in the com­ing weeks af­ter un­veil­ing plans to go pub­lic ear­li­er this month.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.